Cargando…

Vancomycin-resistance gene cluster, vanC, in the gut microbiome of acute leukemia patients undergoing intensive chemotherapy

Two recent reports suggested that the less common, less virulent enterococcal species, Enterococcus gallinarum and E. casseliflavus, with low-level vancomycin resistance due to chromosomally encoded vanC1 and vanC2/3, may influence host immunity. We reported that peri-transplant gut colonization wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Rashidi, Armin, Zhu, Zhigang, Kaiser, Thomas, Manias, Dawn A., Holtan, Shernan G., Rehman, Tauseef Ur, Weisdorf, Daniel J., Khoruts, Alexander, Dunny, Gary M., Staley, Christopher
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6786763/
https://www.ncbi.nlm.nih.gov/pubmed/31600332
http://dx.doi.org/10.1371/journal.pone.0223890
_version_ 1783458136369135616
author Rashidi, Armin
Zhu, Zhigang
Kaiser, Thomas
Manias, Dawn A.
Holtan, Shernan G.
Rehman, Tauseef Ur
Weisdorf, Daniel J.
Khoruts, Alexander
Dunny, Gary M.
Staley, Christopher
author_facet Rashidi, Armin
Zhu, Zhigang
Kaiser, Thomas
Manias, Dawn A.
Holtan, Shernan G.
Rehman, Tauseef Ur
Weisdorf, Daniel J.
Khoruts, Alexander
Dunny, Gary M.
Staley, Christopher
author_sort Rashidi, Armin
collection PubMed
description Two recent reports suggested that the less common, less virulent enterococcal species, Enterococcus gallinarum and E. casseliflavus, with low-level vancomycin resistance due to chromosomally encoded vanC1 and vanC2/3, may influence host immunity. We reported that peri-transplant gut colonization with E. gallinarum and E. casseliflavus is associated with lower mortality after allogeneic hematopoietic cell transplantation (HCT). Because most acute leukemia patients undergoing HCT have received intensive chemotherapy (usually requiring prolonged hospitalization) for their underlying disease before HCT, we hypothesized that some may have acquired vanC-positive enterococci during chemotherapy. Therefore, we evaluated the presence of the vanC gene cluster using vanC1 and vanC2/3 qPCR in thrice-weekly collected stool samples from 20 acute leukemia patients undergoing intensive chemotherapy. We found that an unexpectedly large proportion of patients have detectable vanC1 and vanC2/3 (15% and 35%, respectively) in at least one stool sample. Comparing qPCR results with 16S rRNA gene sequencing results suggested that E. gallinarum may reach high abundances, potentially persisting into HCT and influencing transplant outcomes.
format Online
Article
Text
id pubmed-6786763
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-67867632019-10-19 Vancomycin-resistance gene cluster, vanC, in the gut microbiome of acute leukemia patients undergoing intensive chemotherapy Rashidi, Armin Zhu, Zhigang Kaiser, Thomas Manias, Dawn A. Holtan, Shernan G. Rehman, Tauseef Ur Weisdorf, Daniel J. Khoruts, Alexander Dunny, Gary M. Staley, Christopher PLoS One Research Article Two recent reports suggested that the less common, less virulent enterococcal species, Enterococcus gallinarum and E. casseliflavus, with low-level vancomycin resistance due to chromosomally encoded vanC1 and vanC2/3, may influence host immunity. We reported that peri-transplant gut colonization with E. gallinarum and E. casseliflavus is associated with lower mortality after allogeneic hematopoietic cell transplantation (HCT). Because most acute leukemia patients undergoing HCT have received intensive chemotherapy (usually requiring prolonged hospitalization) for their underlying disease before HCT, we hypothesized that some may have acquired vanC-positive enterococci during chemotherapy. Therefore, we evaluated the presence of the vanC gene cluster using vanC1 and vanC2/3 qPCR in thrice-weekly collected stool samples from 20 acute leukemia patients undergoing intensive chemotherapy. We found that an unexpectedly large proportion of patients have detectable vanC1 and vanC2/3 (15% and 35%, respectively) in at least one stool sample. Comparing qPCR results with 16S rRNA gene sequencing results suggested that E. gallinarum may reach high abundances, potentially persisting into HCT and influencing transplant outcomes. Public Library of Science 2019-10-10 /pmc/articles/PMC6786763/ /pubmed/31600332 http://dx.doi.org/10.1371/journal.pone.0223890 Text en © 2019 Rashidi et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Rashidi, Armin
Zhu, Zhigang
Kaiser, Thomas
Manias, Dawn A.
Holtan, Shernan G.
Rehman, Tauseef Ur
Weisdorf, Daniel J.
Khoruts, Alexander
Dunny, Gary M.
Staley, Christopher
Vancomycin-resistance gene cluster, vanC, in the gut microbiome of acute leukemia patients undergoing intensive chemotherapy
title Vancomycin-resistance gene cluster, vanC, in the gut microbiome of acute leukemia patients undergoing intensive chemotherapy
title_full Vancomycin-resistance gene cluster, vanC, in the gut microbiome of acute leukemia patients undergoing intensive chemotherapy
title_fullStr Vancomycin-resistance gene cluster, vanC, in the gut microbiome of acute leukemia patients undergoing intensive chemotherapy
title_full_unstemmed Vancomycin-resistance gene cluster, vanC, in the gut microbiome of acute leukemia patients undergoing intensive chemotherapy
title_short Vancomycin-resistance gene cluster, vanC, in the gut microbiome of acute leukemia patients undergoing intensive chemotherapy
title_sort vancomycin-resistance gene cluster, vanc, in the gut microbiome of acute leukemia patients undergoing intensive chemotherapy
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6786763/
https://www.ncbi.nlm.nih.gov/pubmed/31600332
http://dx.doi.org/10.1371/journal.pone.0223890
work_keys_str_mv AT rashidiarmin vancomycinresistancegeneclustervancinthegutmicrobiomeofacuteleukemiapatientsundergoingintensivechemotherapy
AT zhuzhigang vancomycinresistancegeneclustervancinthegutmicrobiomeofacuteleukemiapatientsundergoingintensivechemotherapy
AT kaiserthomas vancomycinresistancegeneclustervancinthegutmicrobiomeofacuteleukemiapatientsundergoingintensivechemotherapy
AT maniasdawna vancomycinresistancegeneclustervancinthegutmicrobiomeofacuteleukemiapatientsundergoingintensivechemotherapy
AT holtanshernang vancomycinresistancegeneclustervancinthegutmicrobiomeofacuteleukemiapatientsundergoingintensivechemotherapy
AT rehmantauseefur vancomycinresistancegeneclustervancinthegutmicrobiomeofacuteleukemiapatientsundergoingintensivechemotherapy
AT weisdorfdanielj vancomycinresistancegeneclustervancinthegutmicrobiomeofacuteleukemiapatientsundergoingintensivechemotherapy
AT khorutsalexander vancomycinresistancegeneclustervancinthegutmicrobiomeofacuteleukemiapatientsundergoingintensivechemotherapy
AT dunnygarym vancomycinresistancegeneclustervancinthegutmicrobiomeofacuteleukemiapatientsundergoingintensivechemotherapy
AT staleychristopher vancomycinresistancegeneclustervancinthegutmicrobiomeofacuteleukemiapatientsundergoingintensivechemotherapy